86 related articles for article (PubMed ID: 19015435)
1. Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib.
Donovan JC; Ghazarian DM; Shaw JC
Arch Dermatol; 2008 Nov; 144(11):1524-5. PubMed ID: 19015435
[No Abstract] [Full Text] [Related]
2. Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
Hepper DM; Wu P; Anadkat MJ
J Am Acad Dermatol; 2011 May; 64(5):996-8. PubMed ID: 21496710
[No Abstract] [Full Text] [Related]
3. Severe refractory scarring alopecia associated with combinational use of ficlatuzumab (AV-299) and gefitinib.
Shih YH; Chen PC; Chu CY
J Clin Oncol; 2013 Jul; 31(20):e335-7. PubMed ID: 23715581
[No Abstract] [Full Text] [Related]
4. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
Graves JE; Jones BF; Lind AC; Heffernan MP
J Am Acad Dermatol; 2006 Aug; 55(2):349-53. PubMed ID: 16844529
[TBL] [Abstract][Full Text] [Related]
5. A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
Pongpudpunth M; Demierre MF; Goldberg LJ
J Cutan Pathol; 2009 Dec; 36(12):1303-7. PubMed ID: 19519875
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
DeGrendele H
Clin Lung Cancer; 2003 Sep; 5(2):83-5. PubMed ID: 14596689
[No Abstract] [Full Text] [Related]
7. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Cappuzzo F; Gregorc V; Rossi E; Cancellieri A; Magrini E; Paties CT; Ceresoli G; Lombardo L; Bartolini S; Calandri C; de Rosa M; Villa E; Crino L
J Clin Oncol; 2003 Jul; 21(14):2658-63. PubMed ID: 12860941
[TBL] [Abstract][Full Text] [Related]
9. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
Han SW; Jeon YK; Lee KH; Keam B; Hwang PG; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY
Pharmacogenet Genomics; 2007 May; 17(5):313-9. PubMed ID: 17429313
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib. Still no convincing results in non-small cell lung cancer.
Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
[No Abstract] [Full Text] [Related]
11. Erlotinib-associated alopecia in a lung cancer patient.
Costa DB; Kobayashi S; Schumer ST
J Thorac Oncol; 2007 Dec; 2(12):1136-8. PubMed ID: 18090591
[No Abstract] [Full Text] [Related]
12. Necrotizing vasculitis triggered by gefitinib: an unusual clinical presentation.
Ko JH; Shih YC; Hui RC; Yang CH
J Clin Oncol; 2011 Mar; 29(7):e169-70. PubMed ID: 21149656
[No Abstract] [Full Text] [Related]
13. Biomarkers of response to gefitinib in non-small-cell lung cancer.
Carbone DP
Nat Clin Pract Oncol; 2004 Dec; 1(2):66-7. PubMed ID: 16264818
[No Abstract] [Full Text] [Related]
14. The close correlation between 8-hydroxy-2'-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancer.
Kawahara A; Azuma K; Hattori S; Nakashima K; Basaki Y; Akiba J; Takamori S; Aizawa H; Yanagawa T; Izumi H; Kohno K; Kono S; Kage M; Kuwano M; Ono M
Hum Pathol; 2010 Jul; 41(7):951-9. PubMed ID: 20236686
[TBL] [Abstract][Full Text] [Related]
15. Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer.
Chen CM; Chang JW; Cheung YC; Lin G; Hsieh JJ; Hsu T; Huang SF
Acta Radiol; 2008 Nov; 49(9):991-4. PubMed ID: 18651255
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Apr; 72(1):3-8. PubMed ID: 21216488
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
[No Abstract] [Full Text] [Related]
18. Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.
Reck M; Gatzemeier U
Respir Med; 2005 Mar; 99(3):298-307. PubMed ID: 15733505
[TBL] [Abstract][Full Text] [Related]
19. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
